Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system

Vaccine

Volumn 14, Issue 5, 1996, Pages 428-434

  Fries, L F ^a   Tartaglia, J ^b   Taylor, J ^b   Kauffman, E K ^b   Meignier, B ^c   Paoletti, E ^b   Plotkin, S ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Virogenetics Corporation   (United States)

^c Pasteur Merieux Serums et Vaccins   (France)

Author keywords

Avipoxvirus; Clinical trials; Poxvirus vector; Rabies glycoprotein; Rabies vaccine; Safety

Indexed keywords

RECOMBINANT VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; POXVIRUS; PRIORITY JOURNAL; RABIES; VACCINATION;

EID: 0029947256     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00171-V     Document Type: Article

References (23)

1. Flexner, C. and Moss, B. New Generation Vaccines (ed. Wooddrow, G.C. and Levine, M.M.). Marcel Dekker, Inc. New York, 1990, pp. 189-206
2. Cox, W.I., Tartaglia, L. and Paoletti, E. Recombinant Poxvirus (ed. Binns, M.M. and Smith, G.L.). CRC Press, Boca Raton, FL, 1992, pp. 123-162
3. Boursnell, M.E.G. Recombinant Poxvirus (ed. Binns, M.M. and Smith, G.L.). CRC Press, Boca Raton, FL, 1992, pp. 269-283
4. Baxby, D. and Paoletti, E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 1992, 10, 8-9
5. Taylor, J. and Paoletti, E. Fowlpox virus as a vector in non-avian species. Vaccine 1988, 6, 466-468
6. Taylor, J., Weinberg, R., Languet, B., Desmettre, P. and Paoletti, E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988, 6, 497-503
7. Tartaglia, J., Perkus, M.E., Taylor, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992, 188, 217-232
8. Taylor, J., Trimarchi, C., Weinberg, R. et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991, 9, 190-193
9. Taylor, J., Weinberg, R., Languet, B., Desmettre, P. and Paoletti, E. Technological Advances in Vaccine Development (ed. Lasky, L.). Alan R. Liss, New York, 1988, pp. 321-334
10. Panicali, D. and Paoletti, E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl Acad. Sci. USA 1982, 79, 4927-4931
11. Kieny, M.P., Lathe, R., Drillien, R. et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1994, 312, 163-166
12. Smith, J.S., Yager, P.A. and Baer, G.M. Laboratory Techniques in Rabies (ed. Kaplan, M.M. and Koprowski, H.). WHO, Geneva, 1973, pp. 354-357
13. Steinhoff, M.C., Halsey, N.A., Fries, L.F. et al. The A/Mallard/ 6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. J. Infect. Dis. 1991, 163, 1023-1028
14. Cox, J.H., Dietzschold, B. and Schneider, L.G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect. Immun. 1977, 16, 754-759
15. Cooney, E.L., Collier, A.C., Greenberg, P.D. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337, 567-572
16. Graham, B.S., Belshe, R.B., Clements, M.L. et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 1992, 166, 244-252
17. Etlinger, H.M. and Altenburger, W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991, 9, 470-472
18. Cells, E., Miller, R.W., Wiktor, T.J., Dietzschold, B. and Koprowski, H. Isolation and characterization of human T cell lines and clones reactive to rabies virus: antigen specificity and production of interferon-γ. J. Immunol. 1986, 136, 692-697
19. Lafon, M., Lafage, M., Martinez Arends, A. et al. Evidence for a viral superantigen in humans. Nature 1992, 358, 507-510
20. Perrin, P., Joffret, M.L., Zanetti, C. et al. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees. Vaccine 1991, 9, 549-558
21. Celis, E., Ou, D., Dietzschold, B. and Koprowski, H. Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients. J. Virol. 1988, 62, 3128-3134
22. Nicholson, K.G., Cole, P.J., Turner, G.S. and Harrison, P. Immune responses of humans to a human diploid cell strain of rabies virus vaccine: lymphocyte transformation, production of virus-neutralizing antibody, and induction of interferon. J. Infect. Dis. 1979, 140, 176-182
23. Cadoz, M., Strady, A., Meignier, B. et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339, 1429-1432